Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalNeurologyOpioid Use DisorderTrial Update

Pilot Study on Deep Brain Stimulation for Opioid Use Disorder Initiated

The initiation of a pilot study on deep brain stimulation for opioid use disorder represents a potential shift in treatment paradigms for a challenging condition. Success in this trial could lead to new therapeutic options, impacting existing addiction therapies and strategies for companies in this space.

Published: June 19, 2026
Updated: June 19, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Opioid Use Disorder
Company: Abbott
Asset: Pilot
Trial SummaryCLN

Phase III

Neurology / Opioid Use Disorder

Status

Initiated

Sponsor

Abbott

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The initiation of a pilot study on deep brain stimulation for opioid use disorder represents a potential shift in treatment paradigms for a challenging condition. Success in this trial could lead to new therapeutic options, impacting existing addiction therapies and strategies for companies in this space.

Why it matters

The initiation of a pilot study on deep brain stimulation for opioid use disorder represents a potential shift in treatment paradigms for a challenging condition. Success in this trial could lead to new therapeutic options, impacting existing addiction therapies and strategies for companies in this space.

What changed

Trial Update

Analysis

A pilot study is underway to assess the safety and efficacy of deep brain stimulation targeting the nucleus accumbens in patients with treatment-refractory opioid use disorder.

The initiation of a pilot study on deep brain stimulation for opioid use disorder represents a potential shift in treatment paradigms for a challenging condition. Success in this trial could lead to new therapeutic options, impacting existing addiction therapies and strategies for companies in this space.

Monitor results from this pilot study and any subsequent trials that may expand on these findings.

Related companies & assets

Companies

  • Abbott →

Assets

  • Pilot →

Sources & Humanexa intelligence

Source links

  • Pilot Study on Deep Brain Stimulation for Opioid Use Disorder Initiated ↗

Related Humanexa pages

  • Pilot Study on Deep Brain Stimulation for Opioid Use Disorder Initiated →

Related signals

Trial SummaryCLN

Phase III

gastric cancer therapies

Status

Active

Signal Score

8.4

Clinicalhigh signal

FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression

FTO-mediated demethylation of BCL6 promotes gastric cancer progression by inhibiting ferroptosis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

epithelial ovarian cancer

Status

Active

Signal Score

8.4

Clinicalhigh signal

Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer

Hesperidin-loaded PEGylated PLGA nanoparticles demonstrate improved dissolution and cytotoxicity in EOC models.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.